null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223648

Enrollment

950

Registered

2017-09-07

Start date

2017-08-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : pembrolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
safety efficacy	—

Secondary

Measure	Time frame
efficacy safety safety efficacy efficacy pharmacokinetics efficacy	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results